Fruquintinib, an oral multi-kinase inhibitor targeting VEGF receptors 1-3, was recently demonstrated to enhance the efficacy of PD-1/PD-L1 inhibitors for MSS-CRC (21, 22). The gene discussed is CD274; the disease is colorectal carcinoma.